Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. Dr ...

Please provide your email address to receive an email when new articles are posted on . Ultomiris is a C5 complement inhibitor for neuromyelitis optica spectrum disorder. Trial patients did not ...

TOKYO--(BUSINESS WIRE)--Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the U.S. Food and Drug Administration (FDA) has approved the pH-dependent binding humanized anti-IL-6 receptor ...

Twenty NMOSD patients representing the general patient population were convened to discuss their employment experiences. Participants reported employment issues due to high disease burdens, a lack of ...

TOKYO--(BUSINESS WIRE)--Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced that the results of the SAkuraSky Study (NCT02028884), a global phase III clinical study of satralizumab (development ...

A curative treatment for NMOSD does not currently exist. The main treatment goals are remission, long-term stabilization of disease course by means of relapse prevention and residual symptom relief.

Dublin, Aug. 08, 2025 (GLOBE NEWSWIRE) -- The "Neuromyelitis Optica Spectrum Disorder (NMOSD) - Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering. The report provides an ...

Please provide your email address to receive an email when new articles are posted on . The FDA has announced approval of Soliris injection for treatment of neuromyelitis optica spectrum disorder in ...

The FDA approved a fourth indication for Alexion Pharmaceuticals’ brand-name eculizumab (Soliris) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are ...

A systematic review identified 15 studies, enabling a meta-analysis of 443 NMOSD patients with 639 pregnancies. Rates of pregnancy-related NMOSD relapses were highest during the first 3 months ...

Findings showed treatment with Ultomiris resulted in a statistically significant and clinically meaningful reduction in the risk of relapse compared with the external placebo arm. The Food and Drug ...